Active, not recruitingPhase 1NCT05256290
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Black Diamond Therapeutics, Inc.
- Principal Investigator
- Black Diamond TherapeuticsBlack Diamond Therapeutics
- Intervention
- silevertinib (BDTX-1535) monotherapy(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (20)
- University of Alabama, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- City of Hope Huntington Beach, Huntington Beach, California, United States
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Sibley Memorial Hospital Johns Hopkins Medicine, Washington D.C., District of Columbia, United States
- Mayo Clinic- Jacksonville, Jacksonville, Florida, United States
- Miami Cancer Institute - Baptist Health South Florida, Miami, Florida, United States
- UHP- University of Hawaii Cancer Center, Honolulu, Hawaii, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
- University of Kansas Cancer Center, Fairway, Kansas, United States
- Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic- Rochester, Rochester, Minnesota, United States
- Siteman Cancer Center, St Louis, Missouri, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05256290 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital